No 13 (2009)

We discussed the problem of the use of antibacterial drugs in the treatment of inflammatory bowel disease (IBD). The results of numerous studies on the management of combination antibiotic therapy in addition to treatment by glucocorticosteroids, probiotics, chemotherapeutic agents in various forms of IBD are presented. These experimental and clinical data show that not only antibiotics, as follows a complex of several "technical" methods in patients with IBD will allow to control such a complex system as microflora of gastro-intestinal tract with projected effect.

Anisakidosis is an important medical and social problem for Russian Far East region. Anisakidosis causative agents are nematode larvae of Anisakis, Contracaecum, Pseudoterranova, Hysterothylacium genus, ordinal to Ascaridida, Anisacidae family. Most cases are usually not diagnosed. The article discusses the possibilities of modern diagnosis of the disease, problems of its differential diagnostics with Crohn's disease, treatment and prevention.

We presented data for many studies on the therapeutic efficacy of Hepabene having hepatoprotective, choleretic and spasmolytic properties, in patients with hepatobiliary system diseases. Positive properties of the drug are determined by the qualities of its component plants - Silybum marianum fruit extract and Fumaria officinalis herbs extract. The clinical trials data analyses confirmed the Hepabene effectiveness in the treatment of hepatobiliary system diseases and allowed us to formulate a list of indications for this drug administration. They are all kinds of biliary dyskinesia, chronic liver disease, including steatosis and toxic injury. We highlight the importance of Gepabene administration in patients with liver steatosis caused by metabolic syndrome and type 2 diabetes mellitus.

We present the results of clinical assessment for applicability of Buscopan (Hyoscine butilbromide) in the treatment of chronic pancreatitis with pain syndrome. In the study, including 52 patients, Buscopan significantly reduced the pain intensity in a period of 2 weeks management. The optimal dose was 20 mg 3 times daily, in this case the pain index decreased by 4 times compared with baseline. The frequency of the typical cholinolytic side effects of Buscopan is about 14% regardless of dose.

We presents the results of study on the efficacy and safety of tricomponent therapy with omeprazole, amoxicillin and nifuratel use based on the results of HP-antigen identification in coprofiltrates, which included 32 children and 35 adults with chronic inflammatory diseases of the upper gastrointestinal tract, associated with Helicobacter pylori (HP). Therapy-induced clinical symptoms improvement and erosive and ulcerative mucosal defects epithelization were noted in all patients. Eradication was achieved in 93.8% of children and 88.6% of adults based on the results of histological examination of biopsy samples and immunochromatographic analysis of fecal specimen. Treatment regimen was well torelated, side effects such as nausea and unformed stool was registered only in 6.3% of children and 8.6% of adults. Thus, the nifuratel-based scheme in combination with omeprazole and amoxicillin is effective and safe for the eradication of HP infection in children and adults. Noninvasive immunochromatographic short-term test based on monoclonal antibodies for the HP-antigens identification in fecal specimen can be used for the diagnosis of HP infection and assessment the efficacy of the therapy.

We presented the experience of Roferon-A (recombinant alfa-2a interferon) administration in 69 children with chronic hepatitis C. The data analysis shows the initial remission occur in 49-61% of children at the end of therapy. Remission in 12 months after completion of treatment remained at 22.8-29.6% of patients. It is emphasized that the hitting probability of prolonged remission significantly increases in case of HCV RNA elimination in early stages of interferon therapy.